• home
• About Amunix
• Leadership
• Technology
• Technology
• Partnerships
• News and Events

Investors

Amunix is employee-owned and has no external investors. We are profitable and have $13M in cash and securities.

Amunix has created separate clinical development companies for the development of its XTEN products. Diartis Inc. (www.diartispharma.com ) has Exenatide-XTEN in Phase I clinical trials, and Versartis Inc. (www.versartis.com) has human growth hormone-XTEN in Phase I clinical trials.